-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Cytidine Diphosphocholine Sodium Injection (4ml: 0.5g) has been approved.
Category:
Time：2023-06-13
On June 13, the Class 3 sodium citicoline injection (4 ml: 0.5 g), developed and submitted by Shijiazhuang Fourth Pharmaceutical Group, received drug production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation.
On June 13, the Class 3 sodium citicoline injection (4 ml: 0.5 g), developed and submitted by Shijiazhuang Fourth Pharmaceutical Group, received drug production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation.
It is reported that Sodium Citicoline Injection is primarily used for consciousness disorders following acute traumatic brain injury and brain surgery.
Over the past two years, Shijiazhuang No.4 Pharmaceutical has been driven by innovation to promote high-quality enterprise development, and its R&D innovation has entered a period of intensive harvest. As of now, the company has launched 32 new products this year, and its R&D efficiency continues to remain at the leading level in the same industry nationwide.
Meanwhile, the cumulative number of generic drugs that have passed the evaluation of quality and therapeutic equivalence (or are deemed to have passed such an evaluation) has reached 50 varieties and 65 specifications, continuously injecting new momentum into enterprises’ high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license